Glucose Monitoring for Kids Just Got a Major Upgrade
For years, continuous glucose monitors (CGMs) have been a life-changing tool for adults managing diabetes and metabolic health. But for children, access to these devices has historically required a prescription, a physician's oversight, and a fair amount of navigating the healthcare system. That landscape is shifting in a significant way. Dexcom's Stelo has become the first over-the-counter continuous glucose monitor to receive FDA clearance for use in children, opening the door to app-based glucose tracking for a younger generation of users. This decision has wide-ranging implications for parents, school administrators, pediatric healthcare providers, and employee benefits leaders who manage family health coverage.
What Is Dexcom Stelo and Why Does the FDA Clearance Matter?
Dexcom Stelo is a wearable biosensor that continuously monitors glucose levels throughout the day, syncing data directly to a smartphone app in real time. Unlike traditional CGMs that have required a prescription and were primarily designed for people with diagnosed diabetes, Stelo was initially marketed as an over-the-counter wellness device for adults who wanted to understand how their diet, exercise, and lifestyle affected their blood sugar.
The FDA's decision to extend OTC clearance to children is a landmark moment. It means that caregivers can now purchase the device without needing a doctor's prescription and use it to monitor a child's glucose levels through an intuitive mobile app. This is particularly relevant for children who may be at risk for Type 1 or Type 2 diabetes, those with prediabetes, or simply kids whose parents want a deeper window into their metabolic health.
The clearance represents a meaningful shift in how the FDA views consumer health technology — recognizing that continuous glucose monitoring no longer belongs exclusively in clinical or prescription-only settings.
How App-Based Glucose Tracking Is Changing Pediatric Health Management
The integration of glucose monitoring into smartphone apps is arguably as significant as the hardware itself. With Stelo connected to a mobile app, parents and caregivers can receive real-time alerts, track glucose trends over time, and share data directly with a child's healthcare provider. This kind of continuous visibility was previously only available to families who had already received a diabetes diagnosis and navigated insurance coverage for a prescription device.
For pediatric care teams, app-based data sharing creates new opportunities for proactive health interventions. Instead of relying on a snapshot blood glucose reading taken at a clinic visit, doctors can now review days or weeks of trend data, identify patterns, and make more informed treatment or lifestyle recommendations. This shift toward data-driven pediatric care aligns with broader trends in digital health that prioritize prevention over reactive treatment.
Key Considerations for Schools and Educational Settings
As glucose tracking moves into the hands of more families with children, schools will need to update their policies and infrastructure to accommodate wearable health devices. Several important questions arise in educational environments:
- Device access and use during school hours: Schools will need clear policies on whether students can wear CGM devices during the school day, and how school nurses or staff are expected to interact with device alerts and app data.
- Caregiver and staff communication: With real-time glucose data flowing to a parent's phone, schools may need protocols for how alerts are communicated and acted upon when a child is on campus.
- Data privacy considerations: Health data generated by children is subject to strict privacy protections. Schools and districts will need to ensure that any integration with health apps or data-sharing platforms complies with HIPAA and FERPA requirements.
- Equity of access: While OTC availability lowers one barrier, the cost of devices and compatible smartphones still presents challenges for lower-income families. Schools and public health advocates will need to address these disparities proactively.
What Benefits Leaders and HR Teams Need to Know
For employers who manage family health benefits, the FDA clearance of an OTC CGM for children introduces new coverage and cost considerations. Because Stelo is now available over the counter, it may not automatically be covered under traditional prescription drug or durable medical equipment (DME) benefits. Benefits administrators should evaluate whether their current health plans include provisions for OTC wellness devices and whether updates are needed to accommodate pediatric CGM use.
There is also an opportunity here for forward-thinking benefits leaders to position OTC glucose monitoring as part of a broader preventive health strategy. Covering devices like Stelo for dependents could help identify metabolic issues in children earlier, potentially reducing long-term healthcare costs associated with unmanaged diabetes or insulin resistance.
Healthcare Team Coordination Remains Essential
Despite the excitement around OTC access, pediatric healthcare professionals stress that removing the prescription barrier does not remove the need for medical oversight. CGM data can be highly informative, but interpreting glucose trends in children requires clinical context that parents and caregivers may not have on their own. Pediatricians, endocrinologists, and dietitians should be looped into how families use these devices and what actions they take in response to the data.
Healthcare providers are also encouraged to proactively discuss Stelo with families during well-child visits, particularly for children with risk factors for metabolic disease. Establishing a framework for how app data gets reviewed and acted upon will be critical to ensuring the technology translates into better health outcomes rather than unnecessary anxiety or misinformed decisions.
The Bigger Picture: Wearables Are Entering Childhood Health in a Real Way
Dexcom Stelo's OTC clearance for children is not an isolated event — it is a signal of where pediatric health technology is heading. Smart devices, health apps, and continuous biosensors are increasingly becoming tools that families use alongside traditional healthcare, not just within it. As this ecosystem grows, the challenge for parents, schools, health systems, and insurers will be to build the infrastructure, policies, and support systems that allow these tools to be used safely, equitably, and effectively.
For children who stand to benefit from earlier insight into their metabolic health, this moment marks a genuine step forward. The technology is here. Now comes the harder work of making sure everyone who needs access can actually get it — and use it well.